Financial Report: Biogen

Biogen

2Q Revenues: $2.6 billion (+7%)

2Q Earnings: $927 million (+30%)

FY Revenues: $5.1 billion (+13%)

FY Earnings: $1.7 billion (+45%)

Comments: Multiple sclerosis product sales were $2.1 billion compared to $2.0 billion in the same quarter last year. TECFIDERA revenues in the quarter increased 7% to $883 million. Interferon revenues, including AVONEX and PLEGRIDY, were $690 million, down 9%. TYSABRI revenues were $463 million, down 13%. Revenues relating to RITUXAN and GAZYVA from Biogen’s unconsolidated joint business arrangement were $338 million, up 12%. ELOCTATE revenues were $74 million and ALPROLIX revenues were $54 million in the quarter.